CJC-1295 (No DAC) + Ipamorelin is a blended peptide formulation commonly referenced in preclinical and laboratory research examining growth hormone–related signalling pathways. The combination pairs a short-acting growth hormone–releasing hormone (GHRH) analogue with a selective growth hormone secretagogue, allowing researchers to study pulsatile GH release dynamics in controlled experimental models.
This product is supplied strictly for research and laboratory use only and is not intended for human or veterinary application.
Key Research Notes
Frequently referenced in experimental models assessing synergistic interaction within growth hormone release pathways
CJC-1295 (No DAC) is a short-acting GHRH analogue, while Ipamorelin is a selective GH secretagogue
Blended formulation supplied in lyophilised form for stability and consistency in laboratory environments
Product Information
Compound: 5mg CJC-1295 (No DAC) + 5mg Ipamorelin (blend)
Form: Lyophilised powder
Kit Size: 10 mg blended research vial
Purity: Independently tested (COA available)
Handling: Reconstitution and storage should follow standard laboratory protocols
Quality & Testing
All Paragon compounds undergo third-party analytical testing to verify purity, identity, and consistency. Certificates of Analysis (COAs) are available for transparency and quality assurance.
Important Notice
This compound is sold exclusively for research purposes.
Not approved for human consumption, injection, or therapeutic use.
Purchasers must be 18 years or older and acknowledge responsibility for proper laboratory handling.
CJC-1295 (No DAC) + Ipamorelin is a blended peptide formulation commonly referenced in preclinical and laboratory research examining growth hormone–related signalling pathways. The combination pairs a short-acting growth hormone–releasing hormone (GHRH) analogue with a selective growth hormone secretagogue, allowing researchers to study pulsatile GH release dynamics in controlled experimental models.
This product is supplied strictly for research and laboratory use only and is not intended for human or veterinary application.
Key Research Notes
Frequently referenced in experimental models assessing synergistic interaction within growth hormone release pathways
CJC-1295 (No DAC) is a short-acting GHRH analogue, while Ipamorelin is a selective GH secretagogue
Blended formulation supplied in lyophilised form for stability and consistency in laboratory environments
Product Information
Compound: 5mg CJC-1295 (No DAC) + 5mg Ipamorelin (blend)
Form: Lyophilised powder
Kit Size: 10 mg blended research vial
Purity: Independently tested (COA available)
Handling: Reconstitution and storage should follow standard laboratory protocols
Quality & Testing
All Paragon compounds undergo third-party analytical testing to verify purity, identity, and consistency. Certificates of Analysis (COAs) are available for transparency and quality assurance.
Important Notice
This compound is sold exclusively for research purposes.
Not approved for human consumption, injection, or therapeutic use.
Purchasers must be 18 years or older and acknowledge responsibility for proper laboratory handling.
